Evaluation of Rifampin's Transporter Inhibitory and CYP3A Inductive Effects on the Pharmacokinetics of Venetoclax, a BCL-2 Inhibitor: Results of a Single- and Multiple-Dose Study

Journal of Clinical Pharmacology

Volumn , Issue , 2016, Pages 1335-1343

  Agarwal, Suresh K ^a   Hu, Beibei ^a   Chien, David ^a   Wong, Shekman L ^a   Salem, Ahmed Hamed ^a,b  

^a ABBVIE INC   (United States)

^b Ain Shams University   (Egypt)

Author keywords

ABT 199 GDC 0199; BCL 2; CYP3A4; interaction; OATP; P glycoprotein; pharmacokinetics; rifampin; venetoclax

Indexed keywords

CYTOCHROME P450 3A; MULTIDRUG RESISTANCE PROTEIN; PROTEIN BCL 2; PROTEIN INHIBITOR; RIFAMPICIN; VENETOCLAX;

ADULT; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; COMPARATIVE STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG SCREENING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELIMINATION HALF-LIFE; ELIMINATION RATE CONSTANT; FEMALE; HEADACHE; HUMAN; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPEN STUDY; ORAL CLEARANCE; PHARMACOKINETIC PARAMETERS; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84990250477     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.730     Document Type: Article

References (31)

1. Eichhorst B, Robak T, Montserrat E, et al. Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v78–v84.
2. Billard C. Apoptosis inducers in chronic lymphocytic leukemia. Oncotarget. 2014;5(2):309–325.
3. Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer. 2002;2(9):647–656.
4. Borner C. The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions. Mol Immunol. 2003;39(11):615–647.
5. Cory S, Huang DCS, Adams JM. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene. 2003;22(53):8590–8607.
6. Willis S, Day CL, Hinds MG, et al. The Bcl-2-regulated apoptotic pathway. J Cell Sci. 2003;116(Pt 20):4053–4056.
7. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol. 2008;9(1):47–59.
8. Akl H, Vervloessem T, Kiviluoto S, et al. A dual role for the anti-apoptotic Bcl-2 protein in cancer: mitochondria versus endoplasmic reticulum. Biochim Biophys Acta. 2014;1843(10):2240–2252.
9. Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19:202–208.
10. Vogler M, Dinsdale D, Dyer MJS, et al. ABT-199 selectively inhibits BCL2 but not BCL2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets. Br J Haematol. 2013;163(1):139–142.
11. Davids MS, Letai A, Brown JR. Overcoming stroma-mediated treatment resistance in chronic lymphocytic leukemia through BCL-2 inhibition. Leuk Lymphoma. 2013;54(8):1823–1825.
12. Roberts AW, Davids MS, PageL JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):311–322.
13. Ma S, Brander DM, Seymour JF, et al. Deep and durable responses following venetoclax (ABT-199/GDC-0199) combined with rituximab in patients with relapsed/refractory chronic lymphocytic leukemia: results from a phase 1b study. Blood. 2015;126:830.
14. Konopleva M, Pollyea DA, Potluri J, et al. Efficacy and biological correlates of response in a phase 2 study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016. Submitted.
15. Moreau P, Chanan-Khan A, Roberts, AW, et al. Safety and efficacy of venetoclax (ABT-199/GDC-0199) in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma: phase 1b results. Blood. 2105;126:3038.
16. De Vos S, Swinnen L, Kozloff M, et al. A dose-escalation study of venetoclax (ABT-199/GDC-0199) in combination with bendamustine and rituximab in patients with relapsed or refractory non-Hodgkin's lymphoma. Blood. 2015;126:255.
17. DiNardo C, Pollyea D, Pratz K, et al. A phase 1b study of venetoclax (ABT-199/GDC-0199) in combination with decitabine or azacitidine in treatment-naive patients with acute myelogenous leukemia who are ≥ 65 years and not eligible for standard induction therapy. Blood. 2015;126:327.
18. Choo EF, Boggs J, Zhu C, et al. The role of lymphatic transport on the systemic bioavailability of the Bcl-2 protein family inhibitors navitoclax (ABT-263) and ABT-199. Drug Metab Dispos. 2014;42:207–212.
19. United States Food and Drug Administration. Guidance for Industry. Drug interaction studies - study design, data analysis, implications for dosing, and labeling recommendations. 2012. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf.
20. European Medicines Agency. Guideline on the investigation of drug interactions. 2012. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/07/WC500129606.pdf.
21. Zheng HX, Huang Y, Frassetto LA, et al. Elucidating rifampin's inducing and inhibiting effects on glyburide pharmacokinetics and blood glucose in healthy volunteers: unmasking the differential effects of enzyme induction and transporter inhibition for a drug and its primary metabolite. Clin Pharmacol Ther. 2009;85(1):78–85.
22. Reitman ML, Chu X, Cai X, et al. Rifampin's acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial design. Clin Pharmacol Ther. 2011;89(2):234–242.
23. Furusawa S, Nakano S, Wu J, et al. Potentiation of pirarubicin activity in multidrug resistant cells by rifampicin. Biol Pharm Bull. 1997;20(12):1303–1306.
24. Fardel O, Lecureur V, Loyer P, et al. Rifampicin enhances anti-cancer drug accumulation and activity in multidrug-resistant cells. Biochem Pharmacol. 1995;49(9):1255–1260.
25. Courtois A, Payen L, Vernhet L, et al. Inhibition of multidrug resistance-associated protein (MRP) activity by rifampicin in human multidrug-resistant lung tumor cells. Cancer Lett. 1999;139(1):97–104.
26. Zong J, Pollack G. Modulation of P-glycoprotein transport activity in the mouse blood-brain barrier by rifampin. J Pharmacol Exp Ther. 2003;306(2):556–562.
27. Freise KJ, Jones AK, Eckert D, et al. Relationship of venetoclax dose and exposure to response in relapsed or refractory chronic lymphocytic leukemia and non-Hodgkin's lymphoma subjects. American Association of Cancer Research annual meeting, April 16–20, 2016, New Orleans, LA.
28. Backman JT, Olkkola KT, Neuvonen PJ. Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther. 1996;59:7–13.
29. Yang J, Pradhan RS, Rosen LS, et al. Effect of rifampin on the pharmacokinetics, safety and tolerability of navitoclax (ABT-263), a dual inhibitor of Bcl-2 and Bcl-XL, in patients with cancer. J Clin Pharm Ther. 2014;39(6):680–684.
30. Kaefer A, Yang J, Noertersheuser P, et al. Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of navitoclax (ABT-263) induced thrombocytopenia. Cancer Chemother Pharmacol. 2014;74(3):593–602.
31. Rifadin (rifampin) [US prescribing information]. Bridgewater, NJ: Sanofi-Aventis; February 2013.